Analytical Data
-
Gene name
HLA-A*02:01&B2M&HER2(KIFGSLAFL) Monomer
- Application
-
Alternative Names
HLA-A*0201 & B2M & HER2 (KIFGSLAFL)
-
Species
Human
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
AAA59606.1 (G25-I308)&P61769
-
Expression Region
AAA59606.1 (G25-I308)&P61769 (I21-M119)&KIFGSLAFL
-
Molecular Weight
40-43 kDa and 10 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The study of the HLA-A*02:01/B2M/HER2 (KIFGSLAFL) monomeric recombinant protein is grounded in the critical interplay between the immune system and cancer, particularly in the context of HER2-positive malignancies. HER2 (Human Epidermal Growth Factor Receptor 2) is a well-established oncogene overexpressed in various cancers, including breast and gastric cancers. The presentation of tumor-specific antigens, such as HER2-derived peptides, on Major Histocompatibility Complex (MHC) molecules like HLA-A*02:01 is fundamental for T-cell recognition and targeting of cancer cells. By utilizing a monomeric recombinant protein that combines HLA-A*02:01, beta-2 microglobulin (B2M), and the HER2-derived peptide KIFGSLAFL, researchers aim to investigate the structural and functional characteristics of this complex. Understanding its stability, binding affinity, and immunogenicity can provide insights into T-cell responses, which are pivotal for developing effective immunotherapies. This research may contribute to novel therapeutic strategies, including personalized cancer vaccines, that harness the patient's own immune system to target and eradicate HER2-expressing tumors. Overall, this study bridges basic immunology and clinical oncology, aiming to enhance the efficacy of cancer immunotherapy.
